Purpose: The aim of this study was to estimate a possibility of mycosis fungoides (MF) diagnostics based on protein profiling in blood serum.
Experimental Design: We obtained and analysed samples of blood serum from 23 patients with MF, and 29 psoriasis patients and 22 healthy donors as controls. Protein profiling was carried out using SELDI TOF MS SELDI-TOF and also profiling of 27 cytokines with multiplex immunoassay technology was implemented.
Results: MS data analysis of sera did not give satisfactory statistical discrimination between the groups. Antibody-based cytokine profiling revealed a number of cytokines with a change in their concentrations in both MF and psoriasis (IL-1Ra, IL-4, G-CSF). The C-X-C motif chemokine 10 (IP-10, CXCL10) cytokine had a significantly increased concentration (p<0,001) in samples from MF patients as compared with the other groups.
Conclusions And Clinical Relevance: IP-10 may be considered as a promising biomarker for the differentiation between MF and other skin conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/prca.201000165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.
J Dtsch Dermatol Ges
December 2024
Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, Bochum, Germany.
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.
View Article and Find Full Text PDFCorrigendum: Exploring the educational needs of patients with cutaneous lymphoma using an educational needs assessment tool.
Front Oncol
December 2024
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
[This corrects the article DOI: 10.3389/fonc.2024.
View Article and Find Full Text PDFSkin lymphomas in childhood: We only see what we know, we only know what we see.
J Eur Acad Dermatol Venereol
January 2025
Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Mycosis Fungoides.
J Cutan Med Surg
December 2024
Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
Comparison of Pediatric- and Adult-Onset Mycosis Fungoides Patients in Terms of Clinical Features and Prognosis in a Large Series.
J Cutan Med Surg
December 2024
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Background: Studies comparing the clinical and prognostic differences between pediatric- and adult-onset mycosis fungoides (MF) are limited.
Objectives: To determine the impact of childhood-onset MF on clinical features and disease course in a large series.
Methods: Consecutive MF patients seen in a single centre between 2007 and 2021 were categorized into 3 groups: (i) MF patients diagnosed in the pediatric ages (≤18 years) (pediatric group), (ii) MF patients with disease onset in the pediatric period and diagnosis in adulthood (lately diagnosed pediatric-onset group), and (iii) MF patients with disease onset in the adulthood period (>18 years) (adult-onset group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!